DOI号:10.1016/S1470-2045(18)30295-X
文献链接:[color=rgb(9, 91, 139) !important]LANCET ONCOLOGY[size=0.875][url=]arrow_backView Journal Impact[/url]
Volume19Issue7Page871-879
文献作者:[size=0.875]Zhu, HH (Zhu, Hong-Hu) [color=rgb(9, 91, 139) !important][url=][1][/url]; [size=0.875]Wu, DP (Wu, De-Pei) [color=rgb(9, 91, 139) !important][url=][2][/url]; [size=0.875]Du, X (Du, Xin) [color=rgb(9, 91, 139) !important][url=][3][/url]; [size=0.875]Zhang, X (Zhang, Xi) [color=rgb(9, 91, 139) !important][url=][4][/url]; [size=0.875]Liu, L (Liu, Lin) [color=rgb(9, 91, 139) !important][url=][5][/url]; [size=0.875]Ma, J (Ma, Jun) [color=rgb(9, 91, 139) !important][url=][6][/url]; [size=0.875]Shao, ZH (Shao, Zong-Hong) [color=rgb(9, 91, 139) !important][url=][7][/url]; [size=0.875]Ren, HY (Ren, Han-Yun) [color=rgb(9, 91, 139) !important][url=][8][/url]; [size=0.875]Hu, JD (Hu, Jian-Da) [color=rgb(9, 91, 139) !important][url=][9][/url]; [size=0.875]Xu, KL (Xu, Kai-Lin) [color=rgb(9, 91, 139) !important][url=][10][/url]
备注信息:
[color=rgb(9, 91, 139) !important]Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial |
求助已关闭
50
